Shanghai Pharma's formoterol inhalation solution gains production approval
Shanghai Pharmaceutical Group Co., Ltd. (SSE: 601607) announced that its subsidiary, Shanghai Shinyee Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) to produce Formoterol Fumarate Inhalation Solution. This drug is indicated for the maintenance treatment of airway obstruction in patients with chronic obstructive pulmonary disease (COPD). Developed initially by Mylan Specialty L.P. and marketed as PERFOROMIST®, the drug has seen significant investment from Shanghai Shinyee, with research and development costs totaling CNY 4,405,500. Market data from IQVIA indicates that in 2024, China's hospital procurement of Formoterol Fumarate Inhalation Solution (2ml:20µg) amounted to CNY 461,550,000. The company cautions that sales may not meet expectations due to policy and market uncertainties.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shanghai Pharmaceuticals Holding publishes news
Free account required • Unsubscribe anytime